Stéphanie Forté: New Evidence Strengthens the Case for Hydroxyurea in HbSC Disease
Stéphanie Forté, Principal Researcher at the Innovation Hub at the CHUM Research Center (CRCHUM), shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in British Journal of Haematology, adding:
”Our Quebec study on hydroxyurea in SC disease (HbSC) has just been the subject of an editorial commentary in the British Journal of Haematology.
The message of the commentary is clear: HbSC disease is not a ‘mild’ form of sickle cell disease — it is a biologically distinct entity, long understudied and undertreated out of an abundance of caution.
Our results show a 56 percent reduction in vaso-occlusive crises with hydroxyurea initiation, without complications related to hyperviscosity — a historical fear in this population.
Interestingly, treatment discontinuations were mostly related to modifiable barriers (prescription renewal, education, follow-up) rather than toxicity.
A reminder that patient support is as important as pharmacology.”
Title: Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec
Authors: Alice Girard, Laurianne Charette, Mélissa Haouchine, Laurence Bozec, Mohamed Zakaria Bachir Bouyadjera, Mariane Poitras, Vincent-Thierry Taillefer, Chloé Trudeau, Yves Pastore, Nathalie Letarte, Stéphanie Forté
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM